BACKGROUND: In patients with severe aortic stenosis (AS), long-term data tracking surgically induced effects of afterload reduction on reverse LV remodeling are not available. Echocardiographic data is available short term, but in limited fashion beyond one year. Cardiovascular MRI (CMR) offers the ability to serially track changes in LV metrics with small numbers due to its inherent high spatial resolution and low variability. HYPOTHESIS: We hypothesize that changes in LV structure and function following aortic valve replacement (AVR) are detectable by CMR and once triggered by AVR, continue for an extended period. METHODS: Twenty-four patients of which ten (67 ± 12 years, 6 female) with severe, but compensated AS underwent CMR pre-AVR, 6 months, 1 year and up to 4 years post-AVR. 3D LV mass index, volumetrics, LV geometry, and EF were measured. RESULTS: All patients survived AVR and underwent CMR 4 serial CMR's. LVMI markedly decreased by 6 months (157 ± 42 to 134 ± 32 g/m2, p < 0.005) and continued trending downwards through 4 years (127 ± 32 g/m2). Similarly, EF increased pre to post-AVR (55 ± 22 to 65 ± 11%,(p < 0.05)) and continued trending upwards, remaining stable through years 1-4 (66 ± 11 vs. 65 ± 9%). LVEDVI, initially high pre-AVR, decreased post-AVR (83 ± 30 to 68 ± 11 ml/m2, p < 0.05) trending even lower by year 4 (66 ± 10 ml/m2). LV stroke volume increased rapidly from pre to post-AVR (40 ± 11 to 44 ± 7 ml, p < 0.05) continuing to increase non-significantly through 4 years (49 ± 14 ml) with these LV metrics paralleling improvements in NYHA. However, LVmass/volume, a 3D measure of LV geometry, remained unchanged over 4 years. CONCLUSION: After initial beneficial effects imparted by AVR in severe AS patients, there are, as expected, marked improvements in LV reverse remodeling. Via CMR, surgically induced benefits to LV structure and function are durable and, unexpectedly express continued, albeit markedly incomplete improvement through 4 years post-AVR concordant with sustained improved clinical status. This supports down-regulation of both mRNA and MMP activity acutely with robust suppression long term.
BACKGROUND: In patients with severe aortic stenosis (AS), long-term data tracking surgically induced effects of afterload reduction on reverse LV remodeling are not available. Echocardiographic data is available short term, but in limited fashion beyond one year. Cardiovascular MRI (CMR) offers the ability to serially track changes in LV metrics with small numbers due to its inherent high spatial resolution and low variability. HYPOTHESIS: We hypothesize that changes in LV structure and function following aortic valve replacement (AVR) are detectable by CMR and once triggered by AVR, continue for an extended period. METHODS: Twenty-four patients of which ten (67 ± 12 years, 6 female) with severe, but compensated AS underwent CMR pre-AVR, 6 months, 1 year and up to 4 years post-AVR. 3D LV mass index, volumetrics, LV geometry, and EF were measured. RESULTS: All patients survived AVR and underwent CMR 4 serial CMR's. LVMI markedly decreased by 6 months (157 ± 42 to 134 ± 32 g/m2, p < 0.005) and continued trending downwards through 4 years (127 ± 32 g/m2). Similarly, EF increased pre to post-AVR (55 ± 22 to 65 ± 11%,(p < 0.05)) and continued trending upwards, remaining stable through years 1-4 (66 ± 11 vs. 65 ± 9%). LVEDVI, initially high pre-AVR, decreased post-AVR (83 ± 30 to 68 ± 11 ml/m2, p < 0.05) trending even lower by year 4 (66 ± 10 ml/m2). LV stroke volume increased rapidly from pre to post-AVR (40 ± 11 to 44 ± 7 ml, p < 0.05) continuing to increase non-significantly through 4 years (49 ± 14 ml) with these LV metrics paralleling improvements in NYHA. However, LVmass/volume, a 3D measure of LV geometry, remained unchanged over 4 years. CONCLUSION: After initial beneficial effects imparted by AVR in severe AS patients, there are, as expected, marked improvements in LV reverse remodeling. Via CMR, surgically induced benefits to LV structure and function are durable and, unexpectedly express continued, albeit markedly incomplete improvement through 4 years post-AVR concordant with sustained improved clinical status. This supports down-regulation of both mRNA and MMP activity acutely with robust suppression long term.
Authors: Y Nagatomo; B A Carabello; M L Coker; P J McDermott; S Nemoto; M Hamawaki; F G Spinale Journal: Am J Physiol Heart Circ Physiol Date: 2000-01 Impact factor: 4.733
Authors: S Hinan Ahmed; Leslie L Clark; Weems R Pennington; Carson S Webb; D Dirk Bonnema; Amy H Leonardi; Catherine D McClure; Francis G Spinale; Michael R Zile Journal: Circulation Date: 2006-04-24 Impact factor: 29.690
Authors: Robert W W Biederman; Mark Doyle; June Yamrozik; Ronald B Williams; Vikas K Rathi; Diane Vido; Ketheswaram Caruppannan; Nael Osman; Valerie Bress; Geetha Rayarao; Caroline M Biederman; Sunil Mankad; James A Magovern; Nathaniel Reichek Journal: Circulation Date: 2005-08-30 Impact factor: 29.690
Authors: Lucy E Hudsmith; Steffen E Petersen; Jane M Francis; Matthew D Robson; Stefan Neubauer Journal: J Cardiovasc Magn Reson Date: 2005 Impact factor: 5.364
Authors: Robert W W Biederman; James A Magovern; Saundra B Grant; Ronald B Williams; June A Yamrozik; Diane A Vido; Vikas K Rathi; Geetha Rayarao; Ketheswaram Caruppannan; Mark Doyle Journal: J Cardiothorac Surg Date: 2011-04-14 Impact factor: 1.637
Authors: S P Bishop; P C Powell; N Hasebe; Y T Shen; T A Patrick; L Hittinger; S F Vatner Journal: J Mol Cell Cardiol Date: 1996-01 Impact factor: 5.000
Authors: Victoria Polyakova; Stefan Hein; Sawa Kostin; Tibor Ziegelhoeffer; Jutta Schaper Journal: J Am Coll Cardiol Date: 2004-10-19 Impact factor: 24.094
Authors: Behrus Djavidani; Franz X Schmid; Andreas Keyser; Bernhard Butz; Johannes Seitz; Andreas Luchner; Kurt Debl; Stefan Feuerbach; Wolfgang R Nitz Journal: J Cardiovasc Magn Reson Date: 2004 Impact factor: 5.364
Authors: María José Dalmau; José María González-Santos; Javier López-Rodríguez; María Bueno; Antonio Arribas; Félix Nieto Journal: Interact Cardiovasc Thorac Surg Date: 2007-03-28
Authors: Robert W W Biederman; James A Magovern; Saundra B Grant; Ronald B Williams; June A Yamrozik; Diane A Vido; Vikas K Rathi; Geetha Rayarao; Ketheswaram Caruppannan; Mark Doyle Journal: J Cardiothorac Surg Date: 2011-04-14 Impact factor: 1.637
Authors: Sahadev T Reddy; William Belden; Mark Doyle; Diane V Thompson; Ronald Williams; June Yamrozik; Moneal Shah; Robert W W Biederman Journal: J Interv Card Electrophysiol Date: 2013-03-21 Impact factor: 1.900
Authors: Amr Ei Abouelnour; Mark Doyle; Diane V Thompson; June Yamrozik; Ronald B Williams; Moneal B Shah; Siva Kr Soma; Srinivas Murali; Raymond L Benza; Robert Ww Biederman Journal: Cardiol Res Cardiovasc Med Date: 2017-01-11
Authors: Timothy A Fairbairn; Christopher D Steadman; Adam N Mather; Manish Motwani; Daniel J Blackman; Sven Plein; Gerry P McCann; John P Greenwood Journal: Heart Date: 2013-06-07 Impact factor: 5.994
Authors: S Nordmeyer; C B Lee; L Goubergrits; C Knosalla; F Berger; V Falk; N Ghorbani; H Hireche-Chikaoui; M Zhu; S Kelle; T Kuehne; M Kelm Journal: J Cardiovasc Magn Reson Date: 2021-03-01 Impact factor: 5.364